We recently compiled a list of the 15 Best Stocks to Buy During Recession. In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against the other stocks.

As per BlackRock, 2025 started with a bumpy ride for the US stocks. That being said, the asset manager believes that the sentiment has been a critical driver, but fundamentals seem to be healthy. This makes up for an optimistic longer-run outlook. Despite the tariff shocks creating difficult markets, the firm is constructive in its outlook and opines that volatility is an opportunity to capitalize on stock dispersion. Furthermore, Asia continues to exhibit a diversification opportunity for making investments in the AI theme, with equities providing low correlation to US counterparts.

Amidst Worries, There Is a Silver Lining

The trade and tariff uncertainty, which fueled the early-year volatility, advanced at the beginning of Q2 due to the US tariff pronouncements, according to the investment management company. This resulted in a global market meltdown and revived fears related to recession. However, as the quarter progressed, the tariff tensions took a backseat, and there was some optimism visible in the broader US markets. The asset manager believes that, while tariffs remain a critical measure, the potential for market-supporting policies like deregulation and corporate tax cuts provides some room for emergent optimism.

The firm highlighted the importance of an active approach in a bid to capitalize on inefficiencies and to make precise and intentional decisions amidst historic change and transition. While the results of bilateral tariff negotiations remain unpredictable, having a pulse on company dynamics, mainly when the macro picture remains unclear, can act as a differentiator for portfolios.

Policy Measures Likely to Support Moving Forward

The firm opines that corporate strength has supported the US equities’ momentum, and it comes through in earnings and market share. As per the firm, relatively pro-industry policies have stimulated healthy FCF. Several companies throughout different time frames have deployed the cash for future business growth. Even though the policy uncertainty in the current time of transition led to the pause in large investment decisions, the company believes that moves toward deregulation and the reshoring of supply chains once policy gets settled can result in the revival of CapEx spending throughout industries, such as technology and industrials. Despite tariffs dominating, the asset manager expects that deregulation and other policy priorities can regain attention. The high drive for innovation is the long-term secular trend that can support the US equities.

Our Methodology

To list the 15 Best Stocks to Buy During Recession, we considered the stocks from recession-proof industries such as utilities, consumer defensive, and healthcare. After getting an extensive list of 25-30 stocks, we chose the ones popular among hedge funds. Finally, the stocks were arranged in ascending order of their hedge fund sentiments, as of Q4 2024.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

Abbott Laboratories (NYSE:ABT)

Number of Hedge Fund Holders: 66

Abbott Laboratories (NYSE:ABT) is engaged in discovering, developing, manufacturing, and selling health care products. Josh Jennings from TD Cowen reiterated a “Buy” rating on the company’s stock, with a price objective of $145.00. The analyst’s rating is backed by a combination of factors demonstrating Abbott Laboratories (NYSE:ABT)’s healthy financial performance and growth potential. Despite witnessing significant tariff impacts, the company maintained its guidance for 2025, expects strong EPS, operating margins, and organic sales growth, opines Jennings.

Notably, Abbott Laboratories (NYSE:ABT) expects FY 2025 organic sales growth to be in the range of 7.5% – 8.5%, and an adjusted operating margin of between 23.5% – 24.0% of sales. The company expects FY 2025 adjusted diluted EPS of $5.05 – $5.25. According to Jennings, in Q1 2025, Abbott Laboratories (NYSE:ABT)’s Medical Devices segment demonstrated impressive organic growth, mainly in Diabetes Care, in which continuous glucose monitoring sales surged. Notably, in Diabetes Care, sales of continuous glucose monitors sat at $1.7 billion and increased 18.3% on a reported basis and 21.6% on an organic basis. Also, the company’s 2 new manufacturing and R&D investments in Illinois and Texas, totalling $0.5 billion, are expected to go live by 2025 end.

Diamond Hill Capital, an investment management company, released its Q2 2024 investor letter. Here is what the fund said:

“Abbott Laboratories (NYSE:ABT) is a diversified health care company with an extensive portfolio that spans medical devices, pharmaceuticals, nutritionals and diagnostics. With a substantial portion of its revenues generated internationally, emerging markets contribute about 40% of overall sales. We have always liked Abbott’s diverse mix of businesses and its fundamental growth prospects. The management team has consistently demonstrated skill in capital allocation, highlighted by strategic divestitures such as the European generic business in 2014, and significant acquisitions like St. Jude in 2016.”

Overall ABT ranks 10th on our list of the best stocks to buy during recession. While we acknowledge the potential of ABT as an investment, our conviction lies in the belief that some deeply undervalued AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for a deeply undervalued AI stock that is more promising than ABT but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.